Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Preferential TNFα signaling via TNFR2 regulates epithelial injury and duct obstruction in experimental biliary atresia
Pranavkumar Shivakumar, Tatsuki Mizuochi, Reena Mourya, Sridevi Gutta, Li Yang, Zhenhua Luo, Jorge A. Bezerra
Pranavkumar Shivakumar, Tatsuki Mizuochi, Reena Mourya, Sridevi Gutta, Li Yang, Zhenhua Luo, Jorge A. Bezerra
View: Text | PDF
Research Article Gastroenterology

Preferential TNFα signaling via TNFR2 regulates epithelial injury and duct obstruction in experimental biliary atresia

  • Text
  • PDF
Abstract

Biliary atresia is an obstructive cholangiopathy of infancy that progresses to end-stage cirrhosis. Although the pathogenesis of the disease is not completely understood, previous reports link TNFα to apoptosis of the bile duct epithelium in the presence of IFNγ. Here, we investigate if TNFα signaling regulates pathogenic mechanisms of biliary atresia. First, we quantified the expression of TNFA and its receptors TNFR1 and TNFR2 in human livers and found an increased expression of the receptors at the time of diagnosis. In mechanistic experiments using a neonatal mouse model of rhesus rotavirus–induced (RRV-induced) biliary atresia, the expression of the ligand and both receptors increased 6- to 8-fold in hepatic DCs and NK lymphocytes above controls. The activation of tissue NK cells by RRV-primed DCs was independent of TNFα-TNFR signaling. Once activated, the expression of TNFα by NK cells induced lysis of 55% ± 2% of bile duct epithelial cells, which was completely prevented by blocking TNFα or TNFR2, but not TNFR1. More notably, antibody-mediated or genetic disruption of TNFα-TNFR2 signaling in vivo decreased apoptosis and epithelial injury; suppressed the infiltration of livers by T cells, DCs, and NK cells; prevented extrahepatic bile duct obstruction; and promoted long-term survival. These findings point to a key role for the TNFα/TNFR2 axis on pathogenesis of experimental biliary atresia and identify new therapeutic targets to suppress the disease phenotype.

Authors

Pranavkumar Shivakumar, Tatsuki Mizuochi, Reena Mourya, Sridevi Gutta, Li Yang, Zhenhua Luo, Jorge A. Bezerra

×

Figure 6

Anti-TNFα antibodies suppress the phenotype and bile duct injury.

Options: View larger image (or click on image) Download as PowerPoint
Anti-TNFα antibodies suppress the phenotype and bile duct injury.
(A) Da...
(A) Daily treatment with anti-TNFα antibodies after RRV improved growth, recovery from jaundice, and survival of mice when compared with isotype and saline controls. n = 10–20 mice/group; ***P < 0.001 (lgG vs. TNFα Ab). (B and C) Representative H&E-stained sections of livers and extrahepatic bile ducts show suppression of liver inflammation and no bile duct obstruction in mice receiving anti-TNFα antibodies. Arrows denote intrahepatic bile ducts, and arrowheads show portal inflammation. (D) lmmunofluorescence staining for cytokeratin-19 (CK19, green) and activated caspase 3 (Casp3, red) shows dual-positive cells in bile ducts from lgG1- but not in TNFα Ab–treated mice. Arrowheads, CK19+Casp3+ cells; arrows, periductal Casp3 cells. (E) Representative immunostaining panels show decreased cholangiocyte profiles in livers of TNFα-blocked mice. Arrowheads, increased cholangiocyte profiles; arrows, normal ducts; asterisk, duct lumen; PV, portal vein. n = 4–6 mice/treatment group. Magnification of 400×; scale bar: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts